{"disease":{"id":"mutations","name":"mutations"},"drugs":{"marketed":[{"drug_id":"osimertinib","indication_name":"Adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."},{"drug_id":"osimertinib","indication_name":"Treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."},{"drug_id":"osimertinib","indication_name":"First-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."},{"drug_id":"osimertinib","indication_name":"First-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, in combination with pemetrexed and platinum-based chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."},{"drug_id":"talazoparib-with-enzalutamide","indication_name":"Metastatic castration-resistant prostate cancer (mCRPC) with BRCA1, BRCA2, or ATM gene mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talazoparib with enzalutamide","generic_name":"talazoparib-with-enzalutamide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP enzymes and androgen receptor","drug_class":"PARP inhibitor and androgen receptor inhibitor","quality_score":10,"revenue":"2194","mechanism":""},{"drug_id":"amivantamab","indication_name":"Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rybrevant","generic_name":"AMIVANTAMAB","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"EGFR, MET","drug_class":"","quality_score":59,"revenue":"800","mechanism":"Amivantamab-vmjw targets EGFR and MET, disrupting their signaling and enhancing immune cell-mediated destruction of tumor cells."},{"drug_id":"sevabertinib","indication_name":"Locally advanced or metastatic non-squamous NSCLC with HER2 TKD mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SEVABERTINIB","company_name":"","drug_phase":"marketed","molecular_target":"HER2, EGFR","drug_class":"","quality_score":35,"revenue":null,"mechanism":"Sevabertinib inhibits HER2 and EGFR phosphorylation, blocking downstream signaling and cancer cell proliferation."},{"drug_id":"zongertinib","indication_name":"unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hernexeos","generic_name":"ZONGERTINIB","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Hernexeos works by blocking the HER2 tyrosine kinase domain, which is a protein that helps cancer cells grow and divide."},{"drug_id":"zongertinib","indication_name":"Non-squamous NSCLC with HER2 mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hernexeos","generic_name":"ZONGERTINIB","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Hernexeos works by blocking the HER2 tyrosine kinase domain, which is a protein that helps cancer cells grow and divide."},{"drug_id":"chembl-chembl939","indication_name":"First-line treatment of metastatic NSCLC with specific EGFR mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"GEFITINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"mobocertinib","indication_name":"Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Exkivity","generic_name":"MOBOCERTINIB","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-4","drug_class":"Kinase Inhibitor","quality_score":28,"revenue":null,"mechanism":""},{"drug_id":"pf-06804103","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06804103","generic_name":"pf-06804103","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"EGFR Exon 20 Insertion Mutations","drug_class":"not specified","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"amivantamab-vmjw","indication_name":"Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RYBREVANT","generic_name":"AMIVANTAMAB-VMJW","company_name":"JANSSEN BIOTECH","drug_phase":"marketed","molecular_target":"Epidermal growth factor receptor, Hepatocyte growth factor receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":13,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT03047369","title":"The Myelin Disorders Biorepository Project","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT07039552","title":"Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT00628745","title":"Transthyretin Amyloidosis Outcome Survey (THAOS)","phase":"","overall_status":"COMPLETED","enrollment_count":6718,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02849977","title":"Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers","phase":"","overall_status":"COMPLETED","enrollment_count":5966,"lead_sponsor_name":"Rhythm Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07362225","title":"MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"MPN Research Foundation","has_results":false},{"nct_id":"NCT01443468","title":"Clinical and Genetic Studies of Li-Fraumeni Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03538639","title":"Vascular Disease Discovery Protocol","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT04431024","title":"Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01953926","title":"Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":582,"lead_sponsor_name":"Puma Biotechnology, Inc.","has_results":true},{"nct_id":"NCT03967938","title":"Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":540,"lead_sponsor_name":"Universitair Ziekenhuis Brussel","has_results":false},{"nct_id":"NCT06735391","title":"A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":516,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT01774721","title":"ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":452,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06500676","title":"A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":407,"lead_sponsor_name":"Genfleet Therapeutics (Shanghai) Inc.","has_results":false},{"nct_id":"NCT05607550","title":"Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":398,"lead_sponsor_name":"ArriVent BioPharma, Inc.","has_results":false},{"nct_id":"NCT06908772","title":"Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":390,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT07128199","title":"A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":false},{"nct_id":"NCT06277466","title":"Effect of Mutations in T2DM Susceptibility Genes on the Expression of Susceptibility Genes in Patients With T2DM and Controls","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"The Affiliated Hospital of Xuzhou Medical University","has_results":false},{"nct_id":"NCT04038905","title":"The Use of Digital Genetic Counselor (DGC) for BRCA1/2 Mutation Carrier Testing","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Igentify Ltd","has_results":false},{"nct_id":"NCT01969643","title":"A Safety Study of SGN-LIV1A in Breast Cancer Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":290,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT05796726","title":"Retrospective Chart Review and Historical Comparison of Capmatinib vs. Standard of Care for German Adult Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring METex14 Mutations","phase":"","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02202291","title":"Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon","phase":"NA","overall_status":"COMPLETED","enrollment_count":258,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT03286842","title":"To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":256,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT02699190","title":"LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies","phase":"","overall_status":"COMPLETED","enrollment_count":236,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":true},{"nct_id":"NCT05967689","title":"A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":false},{"nct_id":"NCT04579380","title":"Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":217,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":true},{"nct_id":"NCT05154344","title":"RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU)","phase":"","overall_status":"COMPLETED","enrollment_count":182,"lead_sponsor_name":"Intergroupe Francophone de Cancerologie Thoracique","has_results":false},{"nct_id":"NCT02381886","title":"A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":166,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05364073","title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":160,"lead_sponsor_name":"ArriVent BioPharma, Inc.","has_results":false},{"nct_id":"NCT05132777","title":"Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":155,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT02184195","title":"Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03451877","title":"TGFB1 And LAMA1 Gene Polymorphisms in High Myopia","phase":"NA","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"Ege University","has_results":false},{"nct_id":"NCT02113813","title":"A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":133,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT00277849","title":"Collection of Blood From Persons With Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria Research","phase":"","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT06310382","title":"GH55 for Advanced Cancers With MAPK Mutations: A Study on Safety and Early Results","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Suzhou Genhouse Bio Co., Ltd.","has_results":false},{"nct_id":"NCT03250338","title":"Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Arog Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05241873","title":"(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":103,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT04038502","title":"Carboplatin or Olaparib for BRcA Deficient Prostate Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT03684811","title":"A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Forma Therapeutics, Inc.","has_results":true},{"nct_id":"NCT07410611","title":"ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":84,"lead_sponsor_name":"Hebei Medical University Fourth Hospital","has_results":false},{"nct_id":"NCT06518018","title":"Efficacy and Safety of High-Dose Rate Brachytherapy With Immunotherapy and Chemotherapy as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"The First People's Hospital of Neijiang","has_results":false},{"nct_id":"NCT07505173","title":"Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":74,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT06322095","title":"A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":72,"lead_sponsor_name":"Suzhou Genhouse Bio Co., Ltd.","has_results":false},{"nct_id":"NCT07032727","title":"Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":68,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03679598","title":"Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":true},{"nct_id":"NCT01760655","title":"Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":true},{"nct_id":"NCT07303465","title":"To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Ranok Therapeutics (Hangzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT04316351","title":"Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Guangzhou Institute of Respiratory Disease","has_results":false},{"nct_id":"NCT06701396","title":"Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Vanda Pharmaceuticals","has_results":false},{"nct_id":"NCT01904136","title":"Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}